Brief: Argenx Q4 Net Income USD 532.95 Million
26/02/2026 06:00
Feb 26 (Reuters) - Argenx Q4 operating expenses USD -954.544 million. Q4 total operating income USD 1,322.155 million Q4 basic EPS USD 8.63 Q4 EPS USD 8.02
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles